Published in Bioorg Med Chem Lett on March 27, 2013
Malaria medicines: a glass half full? Nat Rev Drug Discov (2015) 2.53
Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum. Malar J (2013) 0.95
The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. J Int AIDS Soc (2015) 0.91
Network-based gene prediction for Plasmodium falciparum malaria towards genetics-based drug discovery. BMC Genomics (2015) 0.91
Metabolomics in the fight against malaria. Mem Inst Oswaldo Cruz (2014) 0.87
New insight-guided approaches to detect, cure, prevent and eliminate malaria. Protoplasma (2014) 0.81
Identification of New Human Malaria Parasite Plasmodium falciparum Dihydroorotate Dehydrogenase Inhibitors by Pharmacophore and Structure-Based Virtual Screening. J Chem Inf Model (2016) 0.80
Small molecule screen for candidate antimalarials targeting Plasmodium Kinesin-5. J Biol Chem (2014) 0.79
Evaluation of aminohydantoins as a novel class of antimalarial agents. ACS Med Chem Lett (2013) 0.79
Recent advances in malaria genomics and epigenomics. Genome Med (2016) 0.79
Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH). J Med Chem (2015) 0.77
Anti-parasitic Peptides from Arthropods and their Application in Drug Therapy. Front Microbiol (2016) 0.75
PrEP Implementation Science: State-of-the-Art and Research Agenda. J Int AIDS Soc (2015) 0.75
Computational Study on the Effect of Exocyclic Substituents on the Ionization Potential of Primaquine: Insights into the Design of Primaquine-Based Antimalarial Drugs with Less Methemoglobin Generation. Chem Res Toxicol (2015) 0.75
Alternatives to currently used antimalarial drugs: in search of a magic bullet. Infect Dis Poverty (2016) 0.75
Natural product-based synthesis of novel anti-infective isothiocyanate- and isoselenocyanate-functionalized amphilectane diterpenes. Bioorg Med Chem Lett (2015) 0.75
Exploring the scope of new arylamino alcohol derivatives: Synthesis, antimalarial evaluation, toxicological studies, and target exploration. Int J Parasitol Drugs Drug Resist (2016) 0.75
Domestic trends in malaria research and development in China and its global influence. Infect Dis Poverty (2017) 0.75
Virtual-screening workflow tutorials and prospective results from the Teach-Discover-Treat competition 2014 against malaria. F1000Res (2017) 0.75
Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet (2012) 17.62
Discovery of gene function by expression profiling of the malaria parasite life cycle. Science (2003) 10.57
A new world malaria map: Plasmodium falciparum endemicity in 2010. Malar J (2011) 8.65
Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (2010) 8.52
Thousands of chemical starting points for antimalarial lead identification. Nature (2010) 8.28
Glucose-6-phosphate dehydrogenase deficiency. Lancet (2008) 8.26
Artemisinin resistance: current status and scenarios for containment. Nat Rev Microbiol (2010) 6.28
Spiroindolones, a potent compound class for the treatment of malaria. Science (2010) 5.94
Chemical genetics of Plasmodium falciparum. Nature (2010) 5.52
Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell (2007) 5.49
A research agenda to underpin malaria eradication. PLoS Med (2011) 5.34
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. Proc Natl Acad Sci U S A (2008) 4.80
The threat of artemisinin-resistant malaria. N Engl J Med (2011) 4.15
Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: what next? Trends Parasitol (2001) 3.84
A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci U S A (2008) 3.56
Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A (2011) 3.23
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (2011) 3.07
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue. Proc Natl Acad Sci U S A (2011) 2.83
Targeting the hypnozoite reservoir of Plasmodium vivax: the hidden obstacle to malaria elimination. Trends Parasitol (2010) 2.75
The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med (2012) 2.42
A class of potent antimalarials and their specific accumulation in infected erythrocytes. Science (2002) 2.27
Selective and specific inhibition of the plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin. Cell Host Microbe (2012) 2.05
Plasmodium falciparum gametocytes: their longevity and infectivity. Parasitology (1977) 2.02
Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg (2012) 1.97
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem (2011) 1.94
Chloroquine increases Plasmodium falciparum gametocytogenesis in vitro. Parasitology (1999) 1.88
A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J (2012) 1.87
Continuous-flow synthesis of the anti-malaria drug artemisinin. Angew Chem Int Ed Engl (2012) 1.85
G6PD deficiency: global distribution, genetic variants and primaquine therapy. Adv Parasitol (2013) 1.85
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria. J Med Chem (2010) 1.84
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda. Antimicrob Agents Chemother (2010) 1.83
Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol (2007) 1.81
A pre-emptive strike against malaria's stealthy hepatic forms. Nat Rev Drug Discov (2009) 1.77
Malaria gametocytogenesis. Mol Biochem Parasitol (2010) 1.68
Marine actinomycetes: a new source of compounds against the human malaria parasite. PLoS One (2008) 1.67
Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One (2011) 1.60
Understanding the pharmacokinetics of Coartem. Malar J (2009) 1.59
A research agenda for malaria eradication: cross-cutting issues for eradication. PLoS Med (2011) 1.58
Heat shock protein 90: inhibitors in clinical trials. J Med Chem (2010) 1.57
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration. Malar J (2011) 1.56
Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence "transmission blocking" assay. PLoS One (2012) 1.55
Assessment of azithromycin in combination with other antimalarial drugs against Plasmodium falciparum in vitro. Antimicrob Agents Chemother (2002) 1.53
Primaquine in vivax malaria: an update and review on management issues. Malar J (2011) 1.53
The global public health significance of Plasmodium vivax. Adv Parasitol (2012) 1.46
Adherence to a six-dose regimen of artemether-lumefantrine among uncomplicated Plasmodium falciparum patients in the Tigray Region, Ethiopia. Malar J (2011) 1.41
Cytotoxic effect of curcumin on malaria parasite Plasmodium falciparum: inhibition of histone acetylation and generation of reactive oxygen species. Antimicrob Agents Chemother (2006) 1.40
Imidazolopiperazines: hit to lead optimization of new antimalarial agents. J Med Chem (2011) 1.36
The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector. Antimicrob Agents Chemother (2012) 1.35
Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects. Eur J Clin Pharmacol (2006) 1.31
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds. Proc Natl Acad Sci U S A (2012) 1.31
A chemical genomic analysis of decoquinate, a Plasmodium falciparum cytochrome b inhibitor. ACS Chem Biol (2011) 1.31
Prodrugs of bisthiazolium salts are orally potent antimalarials. Proc Natl Acad Sci U S A (2004) 1.29
Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria. Cochrane Database Syst Rev (2005) 1.28
Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice. J Med Chem (2011) 1.28
A systematic approach to understand the mechanism of action of the bisthiazolium compound T4 on the human malaria parasite, Plasmodium falciparum. BMC Genomics (2008) 1.27
Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast. Antimicrob Agents Chemother (2011) 1.27
Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci U S A (2012) 1.26
Imidazolopiperazines: lead optimization of the second-generation antimalarial agents. J Med Chem (2012) 1.22
Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. J Clin Invest (2012) 1.22
Drug screen targeted at Plasmodium liver stages identifies a potent multistage antimalarial drug. J Infect Dis (2012) 1.18
An Invitation to Open Innovation in Malaria Drug Discovery: 47 Quality Starting Points from the TCAMS. ACS Med Chem Lett (2011) 1.18
A high-throughput assay for the identification of malarial transmission-blocking drugs and vaccines. Int J Parasitol (2012) 1.17
A concise synthesis of (+)-artemisinin. J Am Chem Soc (2012) 1.17
Antimalarial efficacy and drug interactions of the novel semi-synthetic endoperoxide artemisone in vitro and in vivo. J Antimicrob Chemother (2007) 1.17
A toolbox to study liver stage malaria. Trends Parasitol (2011) 1.16
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol (2013) 1.15
Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria. Acta Trop (2009) 1.14
Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malar J (2009) 1.14
Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected Rhesus monkeys (Macaca mulatta). Malar J (2011) 1.12
Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria. ACS Med Chem Lett (2011) 1.12
Enhanced gametocyte production in Fansidar-treated Plasmodium falciparum malaria patients: implications for malaria transmission control programmes. Trop Med Int Health (1997) 1.11
Perspective: artemisinin-resistant malaria and the wolf. Am J Trop Med Hyg (2012) 1.11
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malaria. Drugs (2012) 1.08
Control of malaria. Nat Rev Drug Discov (2010) 1.08
New approach for high-throughput screening of drug activity on Plasmodium liver stages. Antimicrob Agents Chemother (2006) 1.08
Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS One (2010) 1.08
A repurposing strategy identifies novel synergistic inhibitors of Plasmodium falciparum heat shock protein 90. J Med Chem (2010) 1.07
Artemisone effective against murine cerebral malaria. Malar J (2010) 1.07
Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. J Med Chem (2010) 1.06
Identification of inhibitors for putative malaria drug targets among novel antimalarial compounds. Mol Biochem Parasitol (2010) 1.06
The structure-activity relationship of the antimalarial ozonide arterolane (OZ277). J Med Chem (2010) 1.06
Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity. J Med Chem (2010) 1.05
Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum. Proc Natl Acad Sci U S A (2012) 1.04
The next opportunity in anti-malaria drug discovery: the liver stage. PLoS Pathog (2011) 1.04
Integrated dataset of screening hits against multiple neglected disease pathogens. PLoS Negl Trop Dis (2011) 1.03
Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a tolerability, safety, and preliminary efficacy study. Antimicrob Agents Chemother (2012) 1.02
Targeting the ERAD pathway via inhibition of signal peptide peptidase for antiparasitic therapeutic design. Proc Natl Acad Sci U S A (2012) 1.02
Candidate selection and preclinical evaluation of N-tert-butyl isoquine (GSK369796), an affordable and effective 4-aminoquinoline antimalarial for the 21st century. J Med Chem (2009) 1.01
Therapeutic potential of boron-containing compounds. Future Med Chem (2009) 1.01
Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malar J (2012) 1.01
Target identification and validation of novel antimalarials. Future Microbiol (2011) 1.00
In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. Antimicrob Agents Chemother (2011) 0.99
Glutathione reductase-catalyzed cascade of redox reactions to bioactivate potent antimalarial 1,4-naphthoquinones--a new strategy to combat malarial parasites. J Am Chem Soc (2011) 0.98
Artemisinin-naphthoquine combination therapy for uncomplicated pediatric malaria: a pharmacokinetic study. Antimicrob Agents Chemother (2012) 0.98
A class of tricyclic compounds blocking malaria parasite oocyst development and transmission. Antimicrob Agents Chemother (2012) 0.98
A chemotype that inhibits three unrelated pathogenic targets: the botulinum neurotoxin serotype A light chain, P. falciparum malaria, and the Ebola filovirus. J Med Chem (2011) 0.98
Whole-cell in vitro screening for gametocytocidal compounds. Future Med Chem (2012) 0.96
A single, low, oral dose of a 5-carbon-linked trioxane dimer orthoester plus mefloquine cures malaria-infected mice. Bioorg Med Chem Lett (2010) 0.95
Road towards new antimalarials - overview of the strategies and their chemical progress. Curr Med Chem (2011) 0.93
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility. Nat Chem Biol (2008) 3.23
The Plasmodium falciparum sexual development transcriptome: a microarray analysis using ontology-based pattern identification. Mol Biochem Parasitol (2005) 3.02
Nucleosome landscape and control of transcription in the human malaria parasite. Genome Res (2010) 1.70
Excess polymorphisms in genes for membrane proteins in Plasmodium falciparum. Science (2002) 1.52
A Plasmodium gene family encoding Maurer's cleft membrane proteins: structural properties and expression profiling. Genome Res (2004) 1.49
In silico discovery of transcription regulatory elements in Plasmodium falciparum. BMC Genomics (2008) 1.48
In vivo transcriptome of Plasmodium falciparum reveals overexpression of transcripts that encode surface proteins. J Infect Dis (2005) 1.46
BRAT-BW: efficient and accurate mapping of bisulfite-treated reads. Bioinformatics (2012) 1.40
Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci U S A (2012) 1.21
The mechanism of action of ramoplanin and enduracidin. Mol Biosyst (2005) 1.21
Polysome profiling reveals translational control of gene expression in the human malaria parasite Plasmodium falciparum. Genome Biol (2013) 1.18
Deciphering the ubiquitin-mediated pathway in apicomplexan parasites: a potential strategy to interfere with parasite virulence. PLoS One (2008) 1.18
NORMAL: accurate nucleosome positioning using a modified Gaussian mixture model. Bioinformatics (2012) 1.09
Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J Am Chem Soc (2002) 1.05
Exploratory analysis of genomic segmentations with Segtools. BMC Bioinformatics (2011) 1.02
Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J Am Chem Soc (2003) 0.99
Nucleosome occupancy at transcription start sites in the human malaria parasite: a hard-wired evolution of virulence? Infect Genet Evol (2010) 0.98
Post-translational modifications in Plasmodium: more than you think! Mol Biochem Parasitol (2009) 0.97
Unraveling the ubiquitome of the human malaria parasite. J Biol Chem (2011) 0.95
In vivo transcriptional profiling of Plasmodium falciparum. Malar J (2004) 0.94
Targeting the Plasmodium ubiquitin/proteasome system with anti-malarial compounds: promises for the future. Infect Disord Drug Targets (2010) 0.89
High-content live cell imaging with RNA probes: advancements in high-throughput antimalarial drug discovery. BMC Cell Biol (2009) 0.87
The E3 ubiquitin ligase XIAP restricts Anaplasma phagocytophilum colonization of Ixodes scapularis ticks. J Infect Dis (2013) 0.87
An apicoplast localized ubiquitylation system is required for the import of nuclear-encoded plastid proteins. PLoS Pathog (2013) 0.86
Characterization of the ubiquitylating components of the human malaria parasite's protein degradation pathway. PLoS One (2012) 0.86
The ubiquitin system: an essential component to unlocking the secrets of malaria parasite biology. Mol Biosyst (2014) 0.85
Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors. J Med Chem (2013) 0.81
Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc. Bioorg Med Chem Lett (2010) 0.79
PuFFIN--a parameter-free method to build nucleosome maps from paired-end reads. BMC Bioinformatics (2014) 0.78
Strand-specific RNA-seq applied to malaria samples. Methods Mol Biol (2012) 0.78
Rational design of highly selective spleen tyrosine kinase inhibitors. J Med Chem (2012) 0.78
Chromatin-driven de novo discovery of DNA binding motifs in the human malaria parasite. BMC Genomics (2011) 0.77
Structures and bioactivities of dihydrochalcones from Metrodorea stipularis. J Nat Prod (2014) 0.77
High content live cell imaging for the discovery of new antimalarial marine natural products. BMC Infect Dis (2012) 0.77
Evaluation of secondary amide replacements in a series of CCR5 antagonists as a means to increase intrinsic membrane permeability. Part 1: Optimization of gem-disubstituted azacycles. Bioorg Med Chem Lett (2009) 0.75
Evaluation of a 4-aminopiperidine replacement in several series of CCR5 antagonists. Bioorg Med Chem Lett (2010) 0.75
Novel hexahydropyrrolo[3,4-c]pyrrole CCR5 antagonists. Bioorg Med Chem Lett (2010) 0.75
Small molecule antagonists of the chemokine receptor CCR5. Curr Top Med Chem (2010) 0.75